Simplify Logo

Full-Time

Sr Director

Clinical Development

Posted on 9/5/2024

Tarsus Pharamceuticals

Tarsus Pharamceuticals

201-500 employees

Biopharmaceuticals for eye and infectious diseases

Hardware
Biotechnology

Compensation Overview

$240k - $336kAnnually

+ Bonus + Stock Equity

Senior, Expert

Irvine, CA, USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Communications
Management
Requirements
  • Advanced degree(s) in relevant field: PharmD, MD or MD/PhD and deep clinical expertise in Ophthalmology and a minimum of 15 years professional pharmaceutical clinical development experience, with a minimum of 10 years leadership in clinical trial management experience required.
  • Extensive experience in early clinical development of ophthalmology and understanding of working in a smaller company, with nimble and innovative mindset.
  • Experienced in industry with expertise in the areas of clinical trial design and execution, and strategic planning; experienced with early to late stage clinical trials, and with the IND to NDA process.
  • External focus to understand the trends in the disease area, treatment paradigms and ability to build relationships with external partners, thought leaders and collaborators outside of Tarsus.
  • Established leadership track record with evidence of excellent performance-based people management experience, problem solving, collaboration, cross functional leadership and effective communication skills.
  • Positive communication style, with a can-do attitude and strong work ethic.
  • Organized with a systematic approach to prioritization.
  • Ability to work collaboratively to project plan, problem solve and deliver results.
  • Expertise with SOPs, GCPs and regulatory and compliance guidelines for clinical trials.
  • Significant knowledge of clinical and outcomes research study design.
  • Proficient knowledge of medical terminology and clinical research industry.
Responsibilities
  • Provides leadership, scientific and strategic planning, direction, and implementation of clinical development activities.
  • Provides clinical leadership and disease area expertise into integrated disease area strategies.
  • Partners closely with KOLs in specific indications.
  • Evaluates strategic options against a given Target Product Profile (TPP).
  • Establishes clinical strategies and designs clinical trial protocols that can rapidly and robustly assess proof-of-concept in early trials as well as designing late stage trials. Ability to develop a range of clinical strategy options, makes recommendations, and facilitates decision making.
  • Leads the clinical science team and oversees the strategy, planning, and resourcing of clinical research activities and clinical trials.
  • Leads and oversees the training of study investigators on protocol and on clinical trial procedures.
  • Authors CSRs, SAPs, Protocols, Clinical Value dossiers, IBs, DSURs, ICFs etc.
  • Leads the analysis and interpretation of clinical data to inform strategic decision-making, identifying trends, and ensure data insights communicated effectively.
  • Conducts research to develop foundational educational material to inform the program strategies.
  • Provides leadership and strategic oversight in the determination of study objectives, strategy, scope, and schedule to meet business needs; align the team on common priorities and initiatives.
  • Partners across functional lines with clinical operations, regulatory affairs, clinical pharmacology, statistics, project management, preclinical science, and others as needed.
  • Serves as program lead on Core teams, investigator meetings, and scientific advisory boards.
  • Ensures the leadership team is kept informed of study progress and that all critical issues are appropriately escalated within the organization.
  • Define and negotiating the scope of work (SOW), budget, pricing, and payment schedules for the clinical vendors.
  • Leads innovation by identifying and integrating cutting-edge technologies and methodologies into clinical trial design.
Tarsus Pharamceuticals

Tarsus Pharamceuticals

View

Tarsus Pharmaceuticals develops treatments for diseases that lack effective solutions, focusing mainly on eye care and infectious diseases. Their key product, XDEMVY, is an FDA-approved eye drop solution used to treat Demodex Blepharitis, a condition affecting the eyelids. The company also has a pipeline of potential treatments for other conditions, including Lyme Disease Prevention and Rosacea. Tarsus differentiates itself from competitors by concentrating on specific medical needs and maintaining a strong commitment to ethical practices and compliance. The goal of Tarsus Pharmaceuticals is to provide effective medical treatments that improve patient outcomes in areas where there are currently few options.

Company Stage

IPO

Total Funding

$610.6M

Headquarters

Irvine, California

Founded

2017

Growth & Insights
Headcount

6 month growth

5%

1 year growth

12%

2 year growth

192%
Simplify Jobs

Simplify's Take

What believers are saying

  • Securing $200 million in non-dilutive financing from Pharmakon Advisors strengthens Tarsus's financial position, enabling further R&D and market expansion.
  • Positive Phase 2a trial results for TP-05 for Lyme Disease prevention indicate promising future product offerings and potential market growth.
  • Recognition through awards like the Zero to Launch Award highlights Tarsus's innovative approach and successful commercialization strategies.

What critics are saying

  • The biopharmaceutical market is highly competitive and capital-intensive, requiring continuous innovation and substantial investment to maintain a competitive edge.
  • Dependence on the success of a limited number of products, such as XDEMVY, makes the company vulnerable to market fluctuations and regulatory changes.

What makes Tarsus Pharamceuticals unique

  • Tarsus Pharmaceuticals focuses on high unmet medical needs in eye care and infectious diseases, setting it apart from competitors with broader but less specialized portfolios.
  • Their flagship product, XDEMVY, is FDA-approved for treating Demodex Blepharitis, a niche condition with limited treatment options, giving them a unique market position.
  • The company's commitment to ethical operations and robust compliance programs ensures trust and reliability among healthcare providers and patients.